Kymera Therapeutics Inc (KYMR)

Apr 15, 2026

Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN

Apr 15, 2026

Apr 14, 2026

KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug - TradingView — Track All Markets

Apr 14, 2026

Apr 13, 2026

Kymera Therapeutics (KYMR) Receives Fast Track Designation for K - GuruFocus

Apr 13, 2026

Apr 13, 2026

Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders - Seeking Alpha

Apr 13, 2026

Apr 13, 2026

RSI Check: What is the earnings history of Kymera Therapeutics IncGap Up & AI Forecasted Entry/Exit Points - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma - Investing News Network

Apr 13, 2026

Apr 13, 2026

Kymera Therapeutics (KYMR) Receives Fast Track Designation for KT-621 - GuruFocus

Apr 13, 2026

Apr 13, 2026

FDA grants fast track status to Kymera’s KT-621 for asthma - Investing.com India

Apr 13, 2026

Apr 13, 2026

FDA grants fast track status to Kymera’s KT-621 for asthma By Investing.com - Investing.com South Africa

Apr 13, 2026

Apr 13, 2026

Aug Closing: Can Kymera Therapeutics Inc weather a recession2026 Market Overview & Long-Term Investment Growth Plans - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Kymera Therapeutics Advances KT-621 with FDA Fast Track Designation for Asthma and Atopic Dermatitis Trials - Quiver Quantitative

Apr 13, 2026

Apr 13, 2026

FDA Fast Track puts Kymera's once-daily oral asthma drug in focus - Stock Titan

Apr 13, 2026

Apr 13, 2026

How Investors Are Reacting To Kymera Therapeutics (KYMR) Gilead Option Exercise And US$45M Milestone - Sahm

Apr 13, 2026

Apr 11, 2026

KYMR SEC FilingsKymera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 11, 2026

Apr 11, 2026

Gilead expands Tempus AI partnership to boost oncology pipeline - MSN

Apr 11, 2026

Apr 10, 2026

Discipline and Rules-Based Execution in KYMR Response - Stock Traders Daily

Apr 10, 2026

Apr 10, 2026

Kymera Therapeutics CBO sells $500k in KYMR stock By Investing.com - Investing.com Australia

Apr 10, 2026

Apr 10, 2026

Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 8,264 Shares - MarketBeat

Apr 10, 2026

Apr 10, 2026

Noah Goodman Sells 2,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat

Apr 10, 2026

Apr 10, 2026

Kymera Therapeutics CBO sells $500k in KYMR stock - Investing.com

Apr 10, 2026

Apr 10, 2026

Kymera Therapeutics (KYMR) CBO trades shares under Rule 10b5-1 plan - Stock Titan

Apr 10, 2026

Apr 10, 2026

KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - Yahoo Finance

Apr 10, 2026

Apr 10, 2026

Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline - Sahm

Apr 10, 2026

Apr 10, 2026

Gilead exercises option to license Kymera’s KT-200 - BioWorld News

Apr 10, 2026

Apr 10, 2026

H.C. Wainwright reiterates Kymera Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Apr 10, 2026

Apr 09, 2026

Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network

Apr 09, 2026

Apr 09, 2026

Kymera Therapeutics (NASDAQ: KYMR) brokered sale notice for 11,611 shares - Stock Titan

Apr 09, 2026

Apr 09, 2026

Gilead Sciences (GILD) Secures Exclusive Rights to KT-200 from K - GuruFocus

Apr 09, 2026

Apr 09, 2026

Gilead exercises option on Kymera’s CDK2 degrader for $45M By Investing.com - Investing.com South Africa

Apr 09, 2026

Apr 09, 2026

Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com

Apr 09, 2026

Apr 09, 2026

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - The Manila Times

Apr 09, 2026

Apr 09, 2026

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ... - Bluefield Daily Telegraph

Apr 09, 2026

Apr 09, 2026

Gilead picks up oral cancer drug KT-200, triggering $45M payout - Stock Titan

Apr 09, 2026

Apr 09, 2026

CEO Change: Is now the right time to enter Kymera Therapeutics IncEarnings Growth Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Aug PostEarnings: What is the earnings history of Kymera Therapeutics Inc2026 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN

Apr 07, 2026

Apr 06, 2026

SG Americas Securities LLC Grows Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Apr 06, 2026

Apr 06, 2026

Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish - MSN

Apr 06, 2026

Apr 04, 2026

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - AOL.com

Apr 04, 2026

Apr 02, 2026

Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat

Apr 02, 2026

Apr 02, 2026

Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,251,134.40 in Stock - MarketBeat

Apr 02, 2026

Apr 02, 2026

Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock - MarketBeat

Apr 02, 2026

Apr 02, 2026

Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares - MarketBeat

Apr 02, 2026